Dr Reddy's Laboratories Total Assets 2006-2019 | RDY

Dr Reddy's Laboratories total assets from 2006 to 2019. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Dr Reddy's Laboratories total assets for the quarter ending September 30, 2019 were $3.311B, a 2.54% increase year-over-year.
  • Dr Reddy's Laboratories total assets for 2019 were $3.259B, a 5.95% decline from 2018.
  • Dr Reddy's Laboratories total assets for 2018 were $3.465B, a 2.21% increase from 2017.
  • Dr Reddy's Laboratories total assets for 2017 were $3.39B, a 8.17% increase from 2016.
Dr Reddy's Laboratories Annual Total Assets
(Millions of US $)
2019 $3,259
2018 $3,465
2017 $3,390
2016 $3,134
2015 $3,126
2014 $2,837
2013 $2,611
2012 $2,348
2011 $2,133
2010 $1,787
2009 $1,646
2008 $2,135
2007 $1,993
2006 $1,546
2005 $671
Dr Reddy's Laboratories Quarterly Total Assets
(Millions of US $)
Q2 2019 $3,311
Q1 2019 $3,295
Q4 2019 $3,259
Q3 2018 $3,258
Q2 2018 $3,229
Q1 2018 $3,372
Q4 2018 $3,465
Q3 2017 $3,540
Q2 2017 $3,400
Q1 2017 $3,380
Q4 2017 $3,390
Q3 2016 $3,345
Q2 2016 $3,311
Q1 2016 $2,896
Q4 2016 $3,134
Q3 2015 $3,141
Q2 2015 $3,091
Q1 2015 $3,164
Q4 2015 $3,126
Q3 2014 $2,925
Q2 2014 $2,848
Q1 2014 $2,890
Q4 2014 $2,837
Q3 2013 $2,715
Q2 2013 $2,575
Q1 2013 $2,536
Q4 2013 $2,611
Q3 2012 $2,531
Q2 2012 $2,467
Q1 2012 $2,279
Q4 2012 $2,348
Q3 2011 $2,310
Q2 2011 $2,198
Q1 2011 $2,197
Q4 2011 $2,133
Q3 2010 $1,874
Q2 2010 $1,792
Q1 2010 $1,765
Q4 2010 $1,787
Q3 2009 $1,565
Q2 2009 $1,711
Q1 2009 $1,761
Q4 2009 $1,646
Q3 2008 $1,983
Q2 2008 $2,057
Q1 2008 $2,120
Q4 2008 $2,135
Q3 2007 $2,003
Q2 2007 $2,038
Q1 2007 $1,927
Q4 2007 $1,993
Q3 2006 $1,969
Q2 2006 $1,808
Q1 2006 $1,689
Q4 2006 $1,546
Q3 2005 $730
Q2 2005 $720
Q1 2005 $711
Q4 2005 $671
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $7.373B $2.225B
Doctor Reddy's is an emerging global pharmaceutical company with proven research capabilities. They are vertically integrated with a presence across the pharmaceutical value chain. They produce finished dosage forms, active pharmaceutical ingredients and biotechnology products and market them globally, with focus on India, US, Europe and Russia. They conduct research in the areas of cancer, diabetes, cardiovascular, inflammation and bacterial infection
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.126B 11.33
Mylan (MYL) United States $11.272B 5.06
Teva Pharmaceutical Industries (TEVA) Israel $11.150B 4.54
Bausch Health Cos (BHC) Canada $10.295B 6.79
ASPEN PHARMACR (APNHY) South Africa $3.515B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.248B 12.07
Amphastar Pharmaceuticals (AMPH) United States $0.926B 48.10
Homology Medicines (FIXX) United States $0.678B 0.00
Assembly Biosciences (ASMB) United States $0.438B 0.00
Voyager Therapeutics (VYGR) United States $0.436B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.414B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.410B 0.56
Sol-Gel Technologies (SLGL) Israel $0.249B 0.00
Akorn (AKRX) United States $0.196B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.148B 0.00
CymaBay Therapeutics (CBAY) United States $0.134B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.121B 0.00
Teligent (TLGT) United States $0.022B 0.00
China Pharma Holdings (CPHI) China $0.020B 0.00